As of the end of 2018, a minimum of 35 distinct treatments targeting CD19 B-cell leukemia had been tested in FDA trials, with two already receiving approval. The introduction of groundbreaking therapies such as Kymriah (Novartis) and Yescarta (Kite Pharma) into the market has significantly increased investment in innovation in the T-cell therapy sector, thereby boosting revenue growth. The sanctioning of initial CAR-T products has opened up profitable opportunities for the approval of future products across a wider range of indications. The annual number of new clinical trials for T-cell therapies is on the rise and has seen a sharp increase in recent years. Besides B-cell cancers, other blood cancers like MM, AML, and solid tumors present substantial business opportunities due to the significant unmet medical needs and lack of competition. T-cell therapies have the potential to transform cancer treatment and provide immense benefits to patients. Currently, 53% of ongoing clinical programs are targeting just 10% of the market. As top CAR-T companies encounter technological hurdles in diversification, solid tumor and TCR therapies are expected to present significant opportunities, encouraging investors to explore these less ventured fields. Investors, both those seeking returns and those with strategic interests, from the biopharma industry have identified adoptive cell therapies as probable pioneer.
The surge in funding for cutting-edge therapy research, the noteworthy sanctioning of CAR T-cell therapies, and key acquisitions in this sector have led to a rise in the number of firms active in the market. As more companies receive approvals and bolster their manufacturing prowess, the competition is expected to escalate during the projected period. Market shares of Kymriah and Yescarta could face heightened competition in the near future due to the launch of newly sanctioned products like JCAR017 by Juno Therapeutics. Companies are implementing various strategies to speed up their production process and secure a foothold in niche market segments. While some firms opt for in-house therapy production, a significant proportion of market players choose to collaborate with third-party service providers, including contract manufacturing organizations. Conversely, numerous companies have established their market presence by acquiring budding CAR T-cell therapy developers. In addition, manufacturers are striving to refine technology and logistics to offer therapies at affordable prices. Given its potential as a one-time curative therapy, the CAR-T sector is bustling with activity. Firms persist in broadening their portfolio in this segment, viewing it as a profitable revenue source in the future years.
Currently, the expense associated with these therapies is considerably high due to the complexity of the products and substantial investments made by companies in crucial studies. This field involves products manufactured using cells from individual patients, so the cost is expected to remain high until the advent of next-generation products like allogeneic T-cell therapies (TCR therapies). The cost of treatment with Yescarta is around USD 373,000, while the cost of treatment with Kymriah is nearly USD 475,000 in the U.S. Considering the high costs and the personalized nature of treatment protocols, the process of insurance approval is predicted to be protracted for CAR-T therapies. Furthermore, according to some clinicians, the adverse reaction of CAR T-cell therapy in patients, such as cytokine release syndrome, might outweigh the potential benefits. Other safety concerns contributing to the extended approval process include fatal instances of tumor lysis syndrome and other organ-specific toxicities, which have been reported in some cases. These factors significantly inflate the price of the final products. Nevertheless, costs are projected to decrease gradually due to heightened market competition and improvements in product manufacturing in the forthcoming years.
This section will provide insights into the contents included in this T-cell therapy market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Market drivers and restraints
Key market opportunities prioritized
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member